How pancreatic polypeptide affects amylin-driven fullness in healthy adults
Official title: Pancreatic Polypeptide as a Modulator of Amylin- Induced Satiety in Healthy Humans
Run by University Hospital, Gentofte, Copenhagen · NCT07506369 · Data updated 2026-11-12
This test will see if giving pancreatic polypeptide together with amylin changes feelings of fullness and how much healthy adults eat.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years to 65 Years |
| Sex | Men only |
| Enrollment | 18 (estimated) |
| Sponsor | University Hospital, Gentofte, Copenhagen Academic / other |
| Locations | 1 site (Hellerup, Capital Region) |
| Status | Recruiting |
| Started | April 2026 |
| Main results expected | October 2026 |
| Study ends | October 2028 |
| Registry record updated | April 1, 2026 |
| Trial ID | NCT07506369 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Healthy men aged 18–65 years with BMI 18–27 kg/m2, body fat under 20%, no major gastrointestinal, hepatic, renal, or pancreatic disease, non-smokers, and able to give informed consent are ideal candidates.
✕Probably not a fit
People outside the trial profile—including women, those with higher BMI or obesity, diabetes requiring treatment, prior GI/pancreatic surgery or disease, recent major weight loss, smokers, or those on interfering medications—are unlikely to match the study population and may not gain direct benefit.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
Healthy male volunteers receive four different five-hour infusions on separate randomized study days: amylin plus pancreatic polypeptide, amylin plus placebo, pancreatic polypeptide plus placebo, and placebo plus placebo. Throughout each study day investigators collect blood samples, measure gallbladder motility, record heart rate and blood pressure, and perform indirect calorimetry to track metabolic effects. The crossover design allows within-person comparison of the separate and combined hormone effects on food intake and related metabolic endpoints. Results will help clarify how these pancreatic hormones interact to control satiety and energy metabolism.
Why it matters
Potential benefit: If successful, the findings could reveal hormone interactions that inform new strategies to reduce appetite and guide obesity treatments.
How similar studies have gone: Amylin (pramlintide) has been shown in prior studies to reduce food intake, but combining amylin with pancreatic polypeptide in humans is relatively novel and not well studied.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Male * Age between 18 and 65 years at the time of inclusion * Body mass index 18-27 kg/m2 * Fat percentage \< 20% * Informed oral and written consent Exclusion Criteria: * Anaemia (haemoglobin below normal range) * History of hepatobiliary and/or gastrointestinal disorder(s) * Kidney disease * Previous gastric or intestinal resection, cholecystectomy and/or any major intra- abdominal surgery (including bariatric surgery) * Previous pancreatic disease and/or neoplasia * Regular tobacco smoking and/or use of other nicotine products * Glycated haemoglobin (HbA1c) ≥48 and/or type 1 diabetes or type 2 diabetes requiring medical treatment * Initiation of special diets, lifestyle changes and/or weight loss \>5% of total body weight within three months prior to or during study period * Any physical or psychological condition or ongoing medication the investigator group suspects would interfere with trial participation
Where it's running
-
Center for Clinical Metabolic Research, Gentofte Hospital
Hellerup, Capital Region, Denmark Recruiting
Study contacts
- Study coordinator: Andreas H Lange
- Email: andreas.holst.lange@rehionh.dk
- Phone: +4553807019
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
How incretin treatments affect muscle mass and function in people with overweight or obesity
This study will see how drugs like semaglutide and tirzepatide influence fat-free mass, muscle strength, and physical function in adults with overweight or obesity.
-
Dose find for remimazolam plus alfentanil for gastroscopy in obese adults
This trial tests what dose of remimazolam besylate with alfentanil best sedates obese adults during gastroscopy.
-
Two-Year Weight Loss With GLP-1 Medications Compared With Sleeve Gastrectomy in Adults
This study compares how much weight adults lose over two years when starting GLP-1 medicines versus adults who had sleeve gastrectomy at the same center.
-
Gut barrier and inflammation after fast-food overfeeding in adults
This study tests whether 14 days of fast-food overfeeding can alter gut barrier function and trigger inflammation in adults who are generally healthy.
-
High BMI and periodontitis in Thai adults under 60
This study tests how common high BMI and periodontitis are among Thai adults aged 18–59 and what factors are linked to them.
-
GLP-1 weight‑loss medicine: finding who will benefit most
This study tests whether a GLP-1 drug called semaglutide helps with weight loss by changing eating behavior, to see which people it helps the most.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.